These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22821590)

  • 1. Using functional genomics to identify drug targets: a Dupuytren's disease example.
    Sedic M; Pavelic SK; Hock K
    Methods Mol Biol; 2012; 910():15-31. PubMed ID: 22821590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent inhibition of TGF-β and mitogen driven signaling cascades in Dupuytren's disease - non-surgical treatment strategies from a signaling point of view.
    Krause C; Kloen P
    Med Hypotheses; 2012 Mar; 78(3):385-8. PubMed ID: 22196988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupuytren's disease therapy: targeting the vicious cycle of myofibroblasts?
    Musumeci M; Vadalà G; Russo F; Pelacchi F; Lanotte A; Denaro V
    Expert Opin Ther Targets; 2015; 19(12):1677-87. PubMed ID: 26690790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional genomics in identification of drug targets in Dupuytren's contracture.
    Sedic M; Jurisic D; Stanec Z; Hock K; Pavelic K; Kraljevic Pavelic S
    Front Biosci (Landmark Ed); 2010 Jan; 15(1):57-64. PubMed ID: 20036806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes.
    Shih B; Wijeratne D; Armstrong DJ; Lindau T; Day P; Bayat A
    J Hand Surg Am; 2009 Jan; 34(1):124-36. PubMed ID: 19121738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a novel gene, MafB, in Dupuytren's disease.
    Lee LC; Zhang AY; Chong AK; Pham H; Longaker MT; Chang J
    J Hand Surg Am; 2006 Feb; 31(2):211-8. PubMed ID: 16473681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome.
    Rehman S; Salway F; Stanley JK; Ollier WE; Day P; Bayat A
    J Hand Surg Am; 2008 Mar; 33(3):359-72. PubMed ID: 18343292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative genomic and transcriptomic analysis of genetic markers in Dupuytren's disease.
    Jung J; Kim GW; Lee B; Joo JWJ; Jang W
    BMC Med Genomics; 2019 Jul; 12(Suppl 5):98. PubMed ID: 31296227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupuytren's: a systems biology disease.
    Rehman S; Goodacre R; Day PJ; Bayat A; Westerhoff HV
    Arthritis Res Ther; 2011; 13(5):238. PubMed ID: 21943049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperbaric oxygen for the treatment of early-phase Dupuytren's contracture.
    Yildiz S; Karacaoğlu E; Pehlivan O
    Microsurgery; 2004; 24(1):26-9. PubMed ID: 14748021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic susceptibility in Dupuytren's disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren's disease.
    Bayat A; Alansar A; Hajeer AH; Shah M; Watson JS; Stanley JK; Ferguson MW; Ollier WE
    J Hand Surg Br; 2002 Feb; 27(1):47-9. PubMed ID: 11895345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association of iron metabolism and Dupuytren's disease.
    Hnanicek J; Cimburova M; Putova I; Svoboda S; Stritesky J; Kratka K; Sosna B; Horak J
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):476-80. PubMed ID: 18194242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis using exon arrays demonstrates an important role for expression of extra-cellular matrix, fibrotic control and tissue remodelling genes in Dupuytren's disease.
    Forrester HB; Temple-Smith P; Ham S; de Kretser D; Southwick G; Sprung CN
    PLoS One; 2013; 8(3):e59056. PubMed ID: 23554969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of myoglobin and ROR2 protein in Dupuytren's disease.
    Forsman M; Pääkkönen V; Tjäderhane L; Vuoristo J; Kallioinen L; Salo T; Kallioinen M; Ryhänen J
    J Surg Res; 2008 May; 146(2):271-5. PubMed ID: 17996904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing.
    Rehman S; Xu Y; Dunn WB; Day PJ; Westerhoff HV; Goodacre R; Bayat A
    Mol Biosyst; 2012 Sep; 8(9):2274-88. PubMed ID: 22772395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease.
    Kraljevic Pavelic S; Sedic M; Hock K; Vucinic S; Jurisic D; Gehrig P; Scott M; Schlapbach R; Cacev T; Kapitanovic S; Pavelic K
    J Pathol; 2009 Mar; 217(4):524-33. PubMed ID: 19089850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole genome and global expression profiling of Dupuytren's disease: systematic review of current findings and future perspectives.
    Shih B; Watson S; Bayat A
    Ann Rheum Dis; 2012 Sep; 71(9):1440-7. PubMed ID: 22772327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors in the pathogenesis of Dupuytren's contracture.
    Al-Qattan MM
    J Hand Surg Am; 2006 Nov; 31(9):1527-34. PubMed ID: 17095386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture.
    Howard JC; Varallo VM; Ross DC; Faber KJ; Roth JH; Seney S; Gan BS
    J Surg Res; 2004 Apr; 117(2):232-8. PubMed ID: 15047128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.